MRONJ
Understanding and managing Medication-Related Osteonecrosis of the Jaw (MRONJ) is an essential component of contemporary dental care, especially relevant with increasing numbers of patients undergoing anti-resorptive or anti-angiogenic drug therapy.
MRONJ, a serious condition characterised by bone necrosis in the jaw, poses significant challenges in dental treatment and patient management.
We emphasise the importance of accurate risk assessment and developing individualised treatment plans, which are essential for the effective management of patients at risk of or suffering from MRONJ.
You will gain insights into the latest best practices and guidelines, equipping you with the necessary tools and knowledge to navigate the challenges posed by MRONJ.
This comprehensive course aims to enhance your clinical skills, improve patient outcomes, and strengthen your role as a essential part of the healthcare team in managing patients affected by MRONJ.
If you're not yet a member of Dentaljuce, we highly recommend you to join and gain access to our comprehensive course on MRONJ.
This course, along with over 100 other CPD courses, is available for a single membership payment.
Aim
The aim of this Dentaljuce module is to enhance dental professionals' understanding and management skills regarding patients at risk of MRONJ, focusing on the identification, risk assessment, and tailored treatment approaches for patients under anti-resorptive or anti-angiogenic drug therapy.
Course objective
- To provide an in-depth understanding of MRONJ, including its definition, pathophysiology, and association with anti-resorptive and anti-angiogenic drugs.
- To develop competence in risk assessment, classification, and evidence-based management strategies for patients at risk of MRONJ.
Anticipated learning outcomes:
The learner will:- Be able to accurately define MRONJ and describe its pathophysiology, particularly in relation to anti-resorptive and anti-angiogenic drugs.
- Gain knowledge on the various anti-resorptive and anti-angiogenic drugs, understanding their mechanisms and how they contribute to the risk of MRONJ.
- Be adept at assessing and classifying patients' risk levels for developing MRONJ, incorporating factors such as type and duration of drug therapy.
- Develop skills in the initial and continuing management of patients at risk of MRONJ, applying current best practices and guidelines.
- Understand the significance of comprehensive documentation in the clinical notes, including risk assessment outcomes and management plans for patients at risk of MRONJ.
GDC Development Outcomes
This CPD will support the learner in meeting the following GDC Development Outcome(s): A B C D.